QLINES Stock Overview
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.78 |
| 52 Week High | kr8.10 |
| 52 Week Low | kr4.78 |
| Beta | 1.05 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -80.96% |
| 3 Year Change | -96.95% |
| 5 Year Change | n/a |
| Change since IPO | -91.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| QLINES | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.0% |
| 1Y | -81.0% | -9.2% | 3.0% |
Return vs Industry: QLINES underperformed the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: QLINES underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| QLINES volatility | |
|---|---|
| QLINES Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: QLINES has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QLINES's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 122 | Jonas Jarvius | qlinea.com |
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. It offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. The company serves healthcare providers.
Q-linea AB (publ) Fundamentals Summary
| QLINES fundamental statistics | |
|---|---|
| Market cap | kr380.89m |
| Earnings (TTM) | -kr238.80m |
| Revenue (TTM) | kr6.32m |
60.2x
P/S Ratio-1.6x
P/E RatioIs QLINES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLINES income statement (TTM) | |
|---|---|
| Revenue | kr6.32m |
| Cost of Revenue | kr8.63m |
| Gross Profit | -kr2.31m |
| Other Expenses | kr236.49m |
| Earnings | -kr238.80m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | -36.53% |
| Net Profit Margin | -3,776.69% |
| Debt/Equity Ratio | 0% |
How did QLINES perform over the long term?
See historical performance and comparison